Unfortunately, anti-cytokine therapy aimed to block TNF-α by administration of Infliximab (monoclonal TNF antibody) or Etanercept (soluble TNF-α receptor) in cancer patients showed only poor ameliorative effects on cachexia pathophysiology (Gueta et al., 2010; Wu et al., 2013), whereas in patients with RA mediated cachexia, Etanercept was shown to reduced mortality (Morgan et al., 2014) and ameliorate the muscular function (Marcora et al., 2006). The gene discussed is TNF; the disease is Cachexia.